HC Wainwright Issues Positive Forecast for TSE:ONC Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Analysts at HC Wainwright boosted their FY2026 EPS estimates for Oncolytics Biotech in a report released on Monday, March 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.39) per share for the year, up from their previous estimate of ($0.40). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2027 earnings at ($0.12) EPS.

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

Oncolytics Biotech stock opened at C$0.91 on Thursday. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The firm has a market cap of C$70.14 million, a price-to-earnings ratio of -2.54 and a beta of 1.35. Oncolytics Biotech has a 1 year low of C$0.86 and a 1 year high of C$2.08. The firm’s 50 day moving average price is C$1.10 and its two-hundred day moving average price is C$1.30.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.